July 31, 2019New England Journal of Medicine748 citationsOpen Access
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
The ibrutinib-rituximab regimen resulted in progression-free survival and overall survival that were superior to those with a standard chemoimmunotherapy regimen among patients 70 years of age or younger with previously untreated CLL. (Funded by the National Cancer Institute and Pharmacyclics; E1912 ClinicalTrials.gov number, NCT02048813.).